{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:35Z","timestamp":1790746775883,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.leukres.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T17:55:45Z","timestamp":1551376545000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Phase 1\/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"DiRienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Zeremski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.leukres.2019.02.012_bib0005","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2019.02.012_bib0010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2014.04.012","article-title":"Are we altering the natural history of primary myelofibrosis?","volume":"38","author":"Savona","year":"2014","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.leukres.2019.02.012_bib0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2019.02.012_bib0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2019.02.012_bib0025","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/leu.2014.220","article-title":"Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? should it?","volume":"28","author":"Barosi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2019.02.012_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","article-title":"Does ruxolitinib prolong the survival of patients with myelofibrosis?","volume":"129","author":"Cervantes","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2019.02.012_bib0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2019.02.012_bib0040","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V122.21.666.666","article-title":"Improved efficacy of combination of JAK2 and Hedgehog inhibitors in myelofibrosis","volume":"122","author":"Bhagwat","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2019.02.012_bib0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.leukres.2019.02.012_bib0050","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2019.02.012_bib0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.leukres.2019.02.012_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"issue":"9","key":"10.1016\/j.leukres.2019.02.012_bib0065","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2019.02.012_bib0070","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of Hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2019.02.012_bib0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OTT.S21957","article-title":"Hedgehog pathway as a drug target: smoothened inhibitors in development","volume":"5","author":"Lin","year":"2012","journal-title":"Onco Targets Ther."},{"issue":"8","key":"10.1016\/j.leukres.2019.02.012_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00096-4","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2019.02.012_bib0085","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-14-1116","article-title":"A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors","volume":"21","author":"Wagner","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.leukres.2019.02.012_bib0090","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428194.2014.984703","article-title":"Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis","volume":"56","author":"Sasaki","year":"2015","journal-title":"Leuk. Lymphoma"}],"updated-by":[{"DOI":"10.1016\/j.leukres.2019.04.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000}}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:49:44Z","timestamp":1668599384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":18,"alternative-id":["S0145212619300384"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.02.012","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.leukres.2019.04.006","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}